Loading...
•
Dec 31, 2020
Adaptive Biotechnologies Q4 2020 Earnings Report
Adaptive Biotechnologies reported a revenue increase of 25% compared to Q4 2019, with clinical sequencing volume up by 41%.
Key Takeaways
Adaptive Biotechnologies reported a 25% increase in revenue for the fourth quarter of 2020, driven by a 69% increase in development revenue. The company launched T-Detect COVID and extended its collaboration with Labcorp.
Revenues of $30.2 million for the fourth quarter, representing a 25% increase over the corresponding period in 2019.
Clinical sequencing volume increased 41% to 4,539 clinical tests delivered in the fourth quarter of 2020, compared to the fourth quarter 2019.
Launched T-Detect™ COVID, first clinical T-cell based test for patients to confirm recent or prior COVID-19 infection.
Extended collaboration agreement with Labcorp to enable broader access to our growing portfolio of immune-driven clinical diagnostic and research products.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...